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A B S T R A C T
Researchers reported that intravenously injected PEGylated colloidal drug carriers lose their
long-circulating characteristic and accumulated extensively in liver when they are admin-
istrated twice in the same animal with certain intervals. This phenomenon was referred
to as the “accelerated blood clearance (ABC) phenomenon”. Some former studies had found
that complement-mediated phagocytosis, activated by antigen–antibody complex, was re-
sponsible for inducing the phenomenon. According to the theory, we have used cobra venom
factor to deplete complement in vivo and to investigate the effect of complement inhibi-
tion on the ABC phenomenon. Rats were administered by injection of cobra venom factor
solution to build up the model of complement exhaustion/inhibition, and the effect of the
inhibition of complement on ABC phenomenon was carried out. It seemed that inhibition
of complement didn’t affect the pharmacokinetic of the first infection. By contrast, in rats
of which complement had been depleted, the second dose of PEGylated nanoemulsions showed
enhanced circulation time compared with normal rats in a complement inhibition-
independent manner, but the ABC phenomenon was not completely eliminated. It indicated
that complement inhibition could certainly weaken the accelerated clearance; mean-
while, there were other factors causing the ABC effect. These findings provide novel insights
into the attenuating of ABC phenomenon and lay foundation for further study of immune
mechanism.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Colloidal drug delivery system endows the drug unique phar-
macokinetic characteristics and effectively improves the
therapeutic index. However, due to the nonspecific adhesion
of plasma proteins on carrier surface, it is easy to be identi-
fied and captured by mononuclear phagocyte system (MPS),
which stimulates the rapid disappearance from the blood cir-
culation. In recent years, PEGylation, namely surface
* Corresponding author. Shenyang Pharmaceutical University, No.103, Wenhua Road, Shenyang 110016, China. Fax: +86 24 23986316.
E-mail address: pharmdeng@gmail.com (Y. Deng).
http://dx.doi.org/10.1016/j.ajps.2016.06.004
1818-0876/© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s ■■ ( 2 0 1 6 ) ■■ –■■
ARTICLE IN PRESS
Please cite this article in press as: Lirong Wang, et al., Effects of complement inhibition on the ABC phenomenon in rats, Asian Journal of Pharmaceutical Sciences (2016),
doi: 10.1016/j.ajps.2016.06.004
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
HOSTED BY
ScienceDirect
modification with amphiphilic polyethylene glycol (PEG), has
been extensively used to protect nanocarriers from the inter-
ference of opsonins, with the aim of increasing the circulation
time [1–4]. Undoubtedly, PEGylation, offering sufficient steric
hindrance and dense hydration layer, brings new vitality for
the application and development of nanocarriers.
It is generally believed that liposomes modified with PEG
have no or lower immunogenicity. Nevertheless, recent reports
have demonstrated that intravenous injection of PEGylated car-
riers or drugs significantly alters the pharmacokinetics and
biodistribution of the second dose (after an interval of several
days), which is referred to as the “accelerated blood clear-
ance (ABC) phenomenon” [5]. Furthermore, this phenomenon
is elicited by pretreatment with not only PEGylated lipo-
somes but also polymeric micelles [6] and PEG-containing
polymeric nanoparticles [7,8]. These changes will affect the
therapeutic outcomes or even cause side effects.Therefore, ABC
phenomenon puts forward unavoidable challenges for further
study of PEGylation technology, which deserves considerable
attention.
The universally accepted mechanism is as follows [9–11]:
primarily injected PEGylated carriers, in a manner of class-2
of thymus-independent antigens (TI-2), stimulate prolifera-
tion and differentiation of specific B cells in the splenic marginal
zone (MZ), and consequently trigger the production of anti-
PEG IgM. Upon administration of the second dose, anti-PEG IgM
instantly recognizes and combines with PEGylated prepara-
tions, which activate the complement system, resulting in
opsonization by C3 fragments and enhanced uptake by Kupffer
cells via complement receptor-mediated endocytosis; there-
fore, ABC phenomenon is elicited. Although the mechanism
of ABC phenomenon has not been elucidated fully, it is obvious
that the activation of complement system plays an essential
role in the accelerated clearance.
Complement is a group of proteins with enzyme activity
when revitalized in the blood and tissue fluid of normal human
and animals. The complement system is broadly involved in
anti-microbial defensive response and immune regulation of
the body, and can mediate injury reaction of immune pathol-
ogy, which is the effective system with important biological
significance in vivo. It is widely accepted that complement ac-
tivation via the classical pathway by antigen–antibody complex
is a vital aspect for ABC phenomenon, while there are no reports
focused on the application of complement inhibitors to study
the relationship between the complement and ABC phenom-
enon so far. Cobra venom factor (CVF) has no neurotoxicity or
cardiotoxicity, and has been widely used for the complement
researches [12–14]. Consequently, we adopted CVF to estab-
lish the rat model of complement inhibition and explored the
role of complement in the ABC phenomenon. In a previous
study, we observed that the repeated intravenous administra-
tion of PEGylated nanoemulsions (PE) evoked a significant
immune response in rats [15]. Therefore, in this research, PE
was used as the suitable carrier to investigate the elimina-
tion or attenuation of ABC phenomenon by complement
inhibition.To evaluate the ABC phenomenon, we calculated the
ratio of the area under the blood concentration–time curve
(AUC)(0–4 h) of the second injection to that of the first one as the
ABC index, due to the high sensitivity of AUC in ANOVA (analy-
sis of variance) tests [16].
2. Materials and methods
2.1. Materials
Tocopheryl nicotinate (TN) was purchased from Northeast Phar-
maceutical Group Co. Ltd. (Shenyang, Liaoning, China). Medium
chain triglycerides (MCT) were from North Medicinal Oil Co.
Ltd. (Tieling, China). Soy lecithin (S75) was from Lipoid GmbH
(America). N-(Carbonyl-methoxypolyethyl-eneglycol-2000)-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (mPEG2000-
DSPE) was purchased from Genzyme Corporation (Cambridge,
MA). Vitamin E acetate (VE) was bought from BASF (Germany).
Glucose injection was produced by the South of Kunming Phar-
maceutical Limited Company. Sterile water for injection was
offered by Shijiazhuang Pharmaceutical Co. Ltd. Four percent
sheep red blood cell and rabbit anti-sheep red blood cell he-
molysin was obtained from Yuhuan South Reagent Factory. CVF
was purchased from Kunming Institute of Animal Science
(Chinese Academy of Science). All the other reagents were of
chromatographic grade.
2.2. Animals
Male Wistar rats (each weighing 180~220 g) were purchased from
the Laboratory Animal Center of Shenyang Pharmaceutical Uni-
versity (Shenyang, Liaoning, China). All animal care and
experiments were carried out in accordance with the guide-
lines of the Animal Welfare Committee of Shenyang
Pharmaceutical University.
2.3. Preparation of PEGylated nanoemulsion
Briefly, TN, MCT, S75 (20.0/100.0/23.3, wt/wt/wt), and mPEG2000-
DSPE (S75 and mPEG2000-DSPE, 9/1, molar ratio) were mixed as
oil phase with constant stirring at 55 °C until dissolved. Sterile
water for the injections, heated to 55 °C, was added.The mixture
was immediately and quickly stirred, and incubated at 55 °C
for 10 minutes to produce the prime emulsion. The entire
product was sonicated using a laboratory ultrasonic cell pul-
verizer (JY92-II; Ningbo Scientz Biotechnology Co., Ltd, Zhejiang,
China), at 200 W for 2 min and at 400 W for 6 min. The ob-
tained emulsion was sized by extrusion through microporous
membrane filters with pore sizes of 0.22 μm and was ad-
justed to an isotonic level with the injection of 50% glucose
before administration. Nicomp 380™ Inc. (Santa Barbara CA,
USA) was used to determine the particle size distribution and
zeta potential. The procedures were performed in the dark.
2.4. Processing method of plasma samples and tissue
samples
The concentration of TN in plasma and tissue was analyzed
by high performance liquid chromatography (HPLC) using a P230
pump and a UV230 UV/Vis detector (Dalian Elite Analytical In-
struments Co., Ltd., Liaoning, China) and separated using a
Hypersil® BDS C18 column (200 mm × 4.6 mm) containing par-
ticles measuring 5 μm in diameter at 30 °C. The ultraviolet
wavelength was 264 nm. The mobile phase was methanol/
isopropanol (80/20, v/v) at a flow rate of 1 ml/min. Before the
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analysis, the plasma samples and tissue samples were treated
as follows: 100 μl of the plasma samples or homogenates
(equivalent to 0.1 g tissue) was mixed with methanol (100 μl),
internal standard (100 μg/ml VE) (100 μl) and n-hexane (600 μl).
The entire mixture was vortexed for 5 min and centrifuged at
10,000 rpm for 10 min.The supernatant (500 μl) was dried using
a CentriVap® Centrifugal Vacuum Concentrator (Labconco Cor-
poration, USA) and dissolved in the mobile phase (100 μl). The
resulting mixture was vortexed for 1 min and centrifuged at
10,000 rpm for 10 min. The supernatant (20 μl) was collected
and used for the HPLC analysis.
2.5. CH50 method for the determination of residual total
complement activity in serum
In this study, we simulated the process of repeated injection
of PE in vivo. The rat serum given PE 7 days before was incu-
bated with PE, and after a certain time the residual total
complement activity was determined by the 50% Hemolytic
Complement (CH50) method. First dose of PE stimulated the
production of anti-PEG IgM, and the antibody was combined
with the second dose to activate the classical pathway of
complement. This resulted in the consumption of comple-
ment components in the blood, which made the residual
complement activity decrease.
CH50 assay was as follows: the complexes formed by the
sheep red blood cell and hemolysin activated the comple-
ment in blood, and then led to the lysis of red cells. Via
determination of the minimal serum level of 50% sensitized
red blood cell (SRBC) hemolysis, the total hemolytic activity
could be obtained. When the number of red cells and hemo-
lysin was invariant, the extent of hemolysis was positively
correlated with the amount and activity of complement within
the given time.
2.5.1. Solution preparation
2.5.1.1. Preparation of buffer solution. A stock solution was pre-
pared by dissolving 2.85 g Na2HPO4 · 12H2O, 0.27 g KH2PO4 and
17.00 g NaCl in 100 ml of distilled water, and was kept at 4 °C
until use. Five milliliters of the stock solution and 0.1 ml 10%
MgSO4 were added to 100 ml flask and diluted with distilled
water to volume, and was utilized within 12 h.
2.5.1.2. Preparation of 2 U/ml hemolysin. Fifty microlitres of he-
molysin (1:4000 titer) were accurately taken to 100 ml flask and
diluted with buffer solution to volume.
2.5.1.3. Preparation of 2% SRBC (5 × 108 cells/ml). Four percent
sheep red blood cells (1 × 109 cells/ml) were mixed with
2 U/ml hemolysin, and incubated at 37 °C for 30 min in a water
bath.
2.5.1.4. Preparation of 50% hemolysis tube. One milliliter 2%
SRBC was blended with 1.5 ml redistilled water and 2 ml buffer
was added to the mixture of same volume, and centrifuged at
2000 rpm for 10 min. The supernatant was needed.
2.5.1.5. Preparation of serum to be tested. Fresh rat blood was
placed still at room temperature for 2 h, and then centri-
fuged at 4000 rpm for 10 min. The supernatant was separated
and stored at −80 °C until use.
2.5.2. Determination of residual total complement activity of
serum
Ninety microliters of serum (inactivated serum, blank serum
and the rat serum given PE 7 days before) were mixed with 10 μl
PE and incubated at 37 °C for 15 min in a water bath.They were
added to the tubes in order, and then blended and placed at
37 °C for 30 min in a water bath.Then the test tubes were taken
out and centrifuged at 3000 rpm for 10 min. The supernatant
was separated to determine the OD values at 542 nm by UV
spectrophotometer.The tube closest to 50% hemolysis tube was
seen as terminal tube.
CH50 value was calculated using the following formula: CH50
(U/ml) = (1 / A) × D, where A represented the amount of serum
and D represented the degree of dilution.
2.6. Inhibition of complement activity assay of CVF
According to the dosage of CVF, 30 healthy Wistar rats were
randomly divided into 6 groups with 5 rats each, namely low
dose groups (2 μg/kg, 5 μg/kg), middle dose groups (10 μg/kg,
20 μg/kg), and high dose groups (50 μg/kg, 100 μg/kg), respec-
tively. CVF (1 mg/ml) was diluted to the desired concentration
with pH 7.4 PBS buffer (0.1 mol/l), and intravenously injected
into the tail vein of rats. At 0 h, 6 h, 1 d, 2 d, 3 d, 5 d, 6 d, 8 d
and 10 d after the injection, blood samples were collected in
a volume of 0.5 ml via eye punctures and then placed in EP
tubes. After coagulation, the samples were centrifuged and mea-
sured for total complement activity (CH50) (Table 1).
2.7. Effects of complement depletion on ABC phenomenon
in rats
Twenty-four healthy Wistar rats were randomly divided into 8
groups with 3 rats each, and injected via tail vein as shown in
Table 2.The single injection groups were first administrated with
5% glucose solution, and repeated injection groups received the
first dose of PE at 5 μmol phospholipids/kg. Six days later, the
Table 1 – CH50 technique measuring complement activation.
Component Number of the test tube
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1:10 serum dilution (ml) – 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5
Buffer (ml) 1.5 1.4 1.3 1.2 1.1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 –
SRBC (ml) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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control groups were given 5% glucose solution, and test groups
were injected with CVF solution at the dose of 20, 50 and 100 μg/
kg respectively. Seven days after first dose, all groups received
an intravenous injection of PE at the dose of 5 μmol phospholipids/
kg.At 0.083,0.25,0.5,1,2 and 4 h after the injection,blood samples
were obtained via eye punctures,and then centrifuged at 4000 rpm
for 10 min to separate the plasma.After obtaining the last blood
sample at 4 h, the livers and spleens were excised and rinsed in
ice-cold normal saline. The blood samples and tissue samples
were treated as “2.4”.
2.8. Effects of different extent of complement inhibition
on ABC phenomenon in rats
Fifteen healthy Wistar rats were randomly divided into 5 groups
with 3 rats each, and injected via tail vein as shown in Table 3.
All groups received the first dose of PE at 5 μmol phospholipids/
kg. Five days later, two groups were injected with 5 and 10 μg/
kg CVF respectively. Six days after the first dose, the control
group was given 5% glucose solution, and the rest of the two
groups were injected with 2 and 5 μg/kg CVF respectively. Seven
days after the first dose, all groups received intravenous in-
jection of PE at the dose of 5 μmol phospholipids/kg. At 0.083,
0.25, 0.5, 1, 2 and 4 h after the injection, blood samples were
obtained via eye punctures, and then centrifuged at 4000 rpm
for 10 min to separate the plasma.After obtaining the last blood
sample at 4 h, the livers and spleens were excised and rinsed
in ice-cold normal saline.The blood samples and tissue samples
were treated as “2.4”.
2.9. Statistical analysis
The data are presented as the mean ± standard deviation. The
statistical analysis was performed using Student’s t-test using
SPSS software. P < 0.05 was considered statistically significant.
3. Results and discussion
3.1. The characteristics of PEGylated nanoemulsion
The lipid emulsion stabilized with emulsifiers such as phos-
pholipids is a promising drug-delivery system. Nanoemulsions
meet most requirements for a good parenteral delivery system
since they are biodegradable, biocompatible, and physically
stable [17,18]. Once PEGylated, PE has been shown to mark-
edly reduce recognition by the MPS and produce a prolonged
blood circulation time when injected intravenously [19,20]. As
Wang et al. reported, the repeated intravenous injection of PE
could elicit a significant immune response [15]. Therefore, we
chose PE as proper nanocarrier to carry out further researches.
Mean diameter and zeta potential of PE were 119.2 ± 1.8 nm and
−30.82 ± 2.77 mV (n = 6), respectively, which showed good
stability.
3.2. The relationship between ABC phenomenon and
complement activation
By calculation, the CH50 value of blank serum was 44.4 U/ml,
and after incubation with PE it turned out to be 40 U/ml, which
indicated that there was no activation or consumption of
complement components in blank serum.While incubated with
rat serum given PE before, the residual total activity de-
creased significantly. The OD value was only 0.069 far from the
50% hemolysis tube (OD value = 0.871); hence, the residual total
activity was much less than 0.670 U/ml (tube no. 15 was deemed
as the terminal tube).The OD value of inactivated serum (56 °C,
30 min) was 0.051. It can be seen that complements were almost
depleted via incubation with rat serum given PE before under
this experimental condition. Meanwhile, it revealed that there
was inevitable connection between complement activation and
Table 2 – Injection scheme of PE to observe the effect of complement depletion on ABC phenomenon.
Group First treatment
(5 μmol
phospholipids/kg)
CVF treatment
1 day before the
second dose
Second dose
(5 μmol
phospholipids/kg)
1 5% glucose solution 5% glucose solution PE
2 5% glucose solution CVF (20 μg/kg)
3 5% glucose solution CVF (50 μg/kg)
4 5% glucose solution CVF (100 μg/kg)
5 PE 5% glucose solution
6 PE CVF (20 μg/kg)
7 PE CVF (50 μg/kg)
8 PE CVF (100 μg/kg)
Table 3 – Injection scheme of PE to observe the effect of different extent of complement inhibition on ABC phenomenon.
Group First treatment
(5 μmol
phospholipids/kg)
CVF treatment
before the second dose
Second dose
(5 μmol
phospholipids/kg)
1 PE 5% glucose solution (1 day before) PE
2 PE 2 μg/kg CVF (1 day before)
3 PE 5 μg/kg CVF (1 day before)
4 PE 5 μg/kg CVF (2 days before)
5 PE 10 μg/kg CVF (2 days before)
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ABC phenomenon induced by the second dose of PEGylated
preparations.
The complement system, an essential part of immune re-
sponse, is activated by trigger enzyme cascade. Complement
works through three means: one is opsonization, that is, via
production of a mass of activated complement proteins and
covalent bonding with pathogens, phagocytosis of mac-
rophages carrying complement receptors is enhanced; another
way is to recruit more phagocytes to the activated sites by some
complement protein fragments with chemotactic properties;
the last is to kill the bacteria through punching holes on their
membrane [21]. Complement can be activated by pathogens
in three different ways: classical pathway, alternative pathway
and mannose-binding pectin pathway. All of them will lead to
the production of a protease called C3 convertase through a
series of reactions. In the early stage of complement activa-
tion, C3 is cleaved into C3a and C3b fragments by C3 convertase
after binding with the surface of pathogen. The C3b frag-
ments are the main effective molecules and can prompt
corresponding phagocytes to function directionally.
Normally, PEG coating can provide dense hydration layer for
nanoemulsions to avoid the adsorption of opsonic proteins ef-
fectively. Our result showed that when PE was incubated with
blank serum, the residual total activity of complement did not
change obviously, namely there was no consumption of comple-
ment. Accordingly, complement did not play a key role in the
metabolism process of the first injected PE. After incubation
with rat serum pre-injected with PE, the residual total activ-
ity of complement was almost 0, which indicated that a great
deal of complement activation and consumption occurred
during the incubation. It can be concluded that complement
activation in blood is one of the important contributors to ABC
phenomenon.
3.3. Effects of CVF on complement activity of rats
Fig. 1 showed that, at 6 h after injection, the total comple-
ment activity of other groups decreased significantly to below
2% besides the low dose groups. The complement activity of
2 μg/kg group was slightly reduced (70.05% ± 14.57%) at 1 d after
injection, and it was 15.64% ± 7.82% of the initial value for 5 μg/
kg group. At the same time, the complement activity of middle
dose groups and high dose groups fell to the smallest,
0.93% ± 0.03% and 0.83% ± 0.17% respectively. Then the total
complement activity rose gradually; it took 2 d to return to
normal level for 2 μg/kg group. As for 5 μg/kg group, 10 μg/kg
group and 20 μg/kg group, it required 5 d, while 50 μg/kg group
and 100 μg/kg group returned to the initial after 6 d and 10 d
respectively. In conclusion, the rat model of complement deple-
tion can be established at 1 d after injection of CVF solution
at a dose of 20, 50 and 100 μg/kg.
In fact, Flexner and Noguchi [12] proposed that the cobra
venom had the anti-complementary activity in 1903, and then
CVF, a certain glycoprotein in cobra venom, proved to be the
active ingredient [13,14]. CVF and factor B can form CVF-Bb
complex with the function of C3 convertase to activate and
deplete complement. CVF has 70% structural homology with
complement C3, which activates the complement in blood via
alternative pathway, resulting in the depletion of C3 and C5~C9
components. When the dose was higher than 10 μg/kg, CVF
could basically deplete complement at 6 h after intravenous
injection into rats. At no less than 20 μg/kg, the complement
activity fell to the smallest at 1 d after administration, and the
recovery time of complement activity extended with increas-
ing dose. However, it is worth mentioning that, as a heterologous
protein, CVF has antigenicity and can elicit the rapid produc-
tion of anti-CVF antibody after injection. In addition,
complement depletion of CVF is systemic, thus increasing the
chances of infection. Considering all these factors, we chose
the smaller effective dose of CVF as complement inhibitor to
reduce the risk of side effects.
3.4. Effects of complement depletion on ABC phenomenon
in rats
With 20, 50 and 100 μg/kg CVF solution to deplete comple-
ment the day before single injection of PE, the concentration–
time curves and tissue distribution of all the groups had no
significant difference; namely, complement depletion had no
effect on the in vivo behavior of single injection. Taking ABC
phenomenon of repeated injection of PE as a reference, ABC
phenomenon of groups pre-injected with CVF was obviously
attenuated, with ABC index increasing more than 3 times and
drug concentration in tissues dramatically reducing (P < 0.05)
(Tables 4 and 5).
As shown in the complement activity–time curves, the
complement activities of each test group were 70.05%, 15.64%,
50.21% and 18.84% of the activity before inhibition in this
regimen, respectively. All the groups induced serious ABC effect
and there was no difference with the control group. This result
indicated that ABC phenomenon did not exactly rely on the
complement activity.
Fig. 1 – Serum complement activity in rats after i.v.
injection of CVF. Data are shown as mean ± S.D., n = 5.
Table 4 – The ABC index of each dosage regimen after
the second injection (n = 3).
Treatment before the
second dose
ABC index(0–4 h)
5% glucose solution 0.12 ± 0.04
20 μg/kg CVF solution 0.54 ± 0.24
50 μg/kg CVF solution 0.51 ± 0.01
100 μg/kg CVF solution 0.54 ± 0.21
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Our experiments showed that the rats injected with (20, 50
and 100 μg/kg) CVF exhibited weakened ABC phenomenon after
repeated injection of PE.The total complement activity in serum
of lower dose groups was reduced in some degree, but it did
not have much influence on the in vivo behavior of repeated
injection of PE, with the strong ABC phenomenon. To sum up,
all the rats without complement depletion could make the same
disposal to repeatedly injected PE, even if there was a differ-
ent total complement activity of serum. As can be seen, residual
complements still played an important part in the clearance
of second dose. This was highly related to the great efficiency
of the body defense mechanism: repeated injection of PE, as
the antigen, and anti-PEG IgM formed antigen–antibody
complex, which could result in quick covalent adhesion of a
small amount of complement proteins distributed in the body.
Some complement fragments with chemotactic property could
also be produced to recruit more phagocytes and mediate the
elimination of immune complex.
Furthermore, the results showed that although CVF could
cause complement depletion, the ABC phenomenon induced
by PE could not be completely eliminated. This suggests that
there are other mechanisms besides opsonization jointly par-
ticipating in the accelerated clearance. Similar conclusion was
obtained in the research of Ishida et al. [22]: in rats that were
splenectomized after the first injection, the ABC phenom-
Table 5 – The ABC index of PE after administrated the
second injection (n = 3).
Treatment before the second dose ABC index (0–4 h)
5% glucose solution 0.12 ± 0.04
2 μg/kg CVF solution (1 day before) 0.08 ± 0.01
5 μg/kg CVF solution (1 day before) 0.10 ± 0.01
5 μg/kg CVF solution (2 days before) 0.12 ± 0.01
10 μg/kg CVF solution (2 days before) 0.11 ± 0.03
Fig. 2 – The blood clearance profile and tissue distribution after i.v. injection of PE in rats. Each group received i.v. injections
of 5% glucose solution or CVF (20 μg/kg) 1 d before the PE treatment. (A) Blood clearance and (B) hepatic and splenic
accumulation 4 h after i.v. injection of the test dose. Data are shown as mean ± S.D., n = 3. P values apply to differences
between the 5% glucose solution treated and CVF (20 μg/kg) treated rats before the second dose.*P < 0.05, **P < 0.01,
***P < 0.001.
Fig. 3 – The blood clearance profile and tissue distribution after i.v. injection of PE in rats. Each group received i.v. injections
of 5% glucose solution or CVF (50 μg/kg) 1 d before the PE treatment. (A) Blood clearance and (B) hepatic and splenic
accumulation 4 h after i.v. injection of the test dose. Data are shown as mean ± S.D., n = 3. P values apply to differences
between the 5% glucose solution treated and CVF (50 μg/kg) treated rats before the second dose.*P < 0.05, **P < 0.01,
***P < 0.001.
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enon could not be totally abolished even though it was greatly
attenuated.Therefore, it can be speculated that the rapid uptake
and clearance of the second dose of PEGylated preparations
are not entirely induced by opsonization related to the comple-
ment system.
The immune system is a complicated and delicate defense
system of the body, consisting of varieties of proteins, cells,
tissues and organs. Complement is the major humoral mol-
ecules of the innate immune system, but beyond that, other
components of the immune system also participate in the iden-
tification and removal of alien invaders. For instance, the first
dose of PEGylated preparations can irritate the lymphocytes
in the thymus or the blood to produce a mass of cytokines or
inflammatory chemokine factors, and then activate Kupffer cells
in a opsonin-independent manner [22,23] (Figs. 2–8).
Above all, it can be concluded that complement activity is
not the unique factor affecting the ABC phenomenon, and there
are other contributors playing an important role in the induc-
tion of ABC phenomenon. In this study, we discussed the crucial
part that complement system plays in the phenomenon, and
further perfected the possible mechanism of ABC phenom-
enon. Meanwhile, the study found that the strategy of
complement inhibition can attenuate the ABC phenomenon
in some degree, which provides references for making admin-
istration regimens of PEGylated preparations.
4. Conclusion
The complement activation in the blood after repeated injec-
tion of PEGylated preparations is one of the vital reasons
resulting in the ABC phenomenon. The rat model of comple-
ment depletion can be well established at 1 d after injection
of CVF solution at higher dose. However, the strength of ABC
phenomenon does not entirely rely on the extent of the comple-
ment inhibition, and there are other contributors for the
induction of ABC phenomenon besides opsonization. These
findings may provide new perspectives in abrogating or at-
tenuating the ABC phenomenon and contribute to the research
of immune mechanism.
Fig. 4 – The blood clearance profile and tissue distribution after i.v. injection of PE in rats. Each group received i.v. injections
of 5% glucose solution or CVF (100 μg/kg) 1 d before the PE treatment. (A) Blood clearance and (B) hepatic and splenic
accumulation 4 h after i.v. injection of the test dose. Data are shown as mean ± S.D., n = 3. P values apply to differences
between the 5% glucose solution treated and CVF (100 μg/kg) treated rats before the second dose.*P < 0.05, **P < 0.01,
***P < 0.001.
Fig. 5 – The blood clearance profile and tissue distribution after i.v. injection of PE in rats. Each group received i.v. injections
of 5% glucose solution or CVF (2 μg/kg) 1 d before the second treatment of PE. (A) Blood clearance and (B) hepatic and splenic
accumulation 4 h after i.v. injection of the test dose. Data are shown as mean ± S.D., n = 3.
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Fig. 6 – The blood clearance profile and tissue distribution after i.v. injection of PE in rats. Each group received i.v. injections
of 5% glucose solution or CVF (5 μg/kg) 1 d before the second treatment of PE. (A) Blood clearance and (B) hepatic and splenic
accumulation 4 h after i.v. injection of the test dose. Data are shown as mean ± S.D., n = 3.
Fig. 7 – The blood clearance profile and tissue distribution after i.v. injection of PE in rats. Each group received i.v. injections
of 5% glucose solution or CVF (5 μg/kg) 2 d before the second treatment of PE. (A) Blood clearance and (B) hepatic and splenic
accumulation 4 h after i.v. injection of the test dose. Data are shown as mean ± S.D., n = 3.
Fig. 8 – The blood clearance profile and tissue distribution after i.v. injection of PE in rats. Each group received i.v. injections
of 5% glucose solution or CVF (10 μg/kg) 2 d before the second treatment of PE. (A) Blood clearance and (B) hepatic and
splenic accumulation 4 h after i.v. injection of the test dose. Data are shown as mean ± S.D., n = 3.
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